Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riliprubart - Sanofi

Next Previous
Drug Profile

Riliprubart - Sanofi

Alternative Names: BIVV-020; SAR-445088; TNT-020

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ; Sanofi; Sanofi-Aventis Recherche & Developpement
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Idiopathic thrombocytopenic purpura; Renal transplant rejection
  • Discontinued Autoimmune haemolytic anaemia

Most Recent Events

  • 01 Apr 2025 Phase-III clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (Treatment-experienced) in Canada and China (SC) (NCT06859099)
  • 05 Mar 2025 Sanofi plans a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy (SC, Injection) in April 2025 (NCT06859099, EudraCT2024-517032-22-00)
  • 04 Mar 2025 Bioverativ terminates a phase I trial in Autoimmune haemolytic anaemia in the Netherlands, Germany, Italy, Norway, the United Kingdom (IV) due to the business decision, not related to any safety or efficacy issues (NCT04802057)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top